81 completed, 21 unknown, 20 terminated, 15 recruiting. 158 Phase 3, 21 Phase 2.
Follow Neoplasms, Connective Tissue: new trials by email Literature Review of Neoplasms, Connective Tissue trials Research Report on Neoplasms, Connective Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DEPART Study at Yale Radiation Therapy - Dupuytren's Contracture | Phase 3 | Not yet recruiting | Yale University | 158 | 2026-11-01 | 2026-10-13 |
| Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse Experimental group : Cabometyx ® 40mg/m2/day (Max: 60mg/day) , Treatment schedule : Daily**, day 1-28 during 4 weeks (ie. 1 cycle) during 12 cycles - Osteosarcoma, Pediatric Osteosarcoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 530 | 2026-10-07 | 2026-10-26 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) Velzatinib, Imatinib - Gastrointestinal Stromal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 800 | 2026-07-27 | 2026-10-23 |
| Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) NB003, regorafenib - GIST - Gastrointestinal Stromal Tumor, Advanced | Phase 2 / Phase 3 | Recruiting | Ningbo Newbay Technology Development Co., Ltd | 255 | 2026-05-11 | 2026-11-12 |
| Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma TBI-1301, Cyclophosphamide, Fludarabine - Synovial Sarcomas | Phase 3 | Recruiting | Takara Bio Inc. | 5 | 2026-01-05 | 2026-09-28 |
| A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy IDRX-42, Sunitinib - Gastrointestinal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2025-12-03 | 2026-10-05 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure HS-20093, Gemcitabine combined with docetaxel - Osteosarcoma | Phase 3 | Completed | Hansoh BioMedical R&D Company | 122 | 2025-04-25 | 2026-10-19 |
| A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism Ersodetug - Tumor Hyperinsulinism (Tumor HI) | Phase 3 | Recruiting | Rezolute | 16 | 2025-04-16 | 2026-09-28 |
| Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) Emactuzumab, Placebo - TGCT | Phase 3 | Active not recruiting | SynOx Therapeutics Limited | 128 | 2024-10-09 | 2026-07-29 |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas Biospecimen Collection, Diagnostic Imaging Testing, Doxorubicin - Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 365 | 2024-09-11 | 2026-11-12 |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy Misoprostol 200mcg Tab, Oxytocin - Myoma;Uterus | Phase 3 | Unknown | Cairo University | 56 | 2024-03-01 | 2024-03-22 |
| A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib Ripretinib, Sunitinib - GIST | Phase 3 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 54 | 2023-12-13 | 2025-12-17 |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) EN3835, Placebo - Plantar Fibromatosis, Ledderhose Disease | Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 436 | 2023-11-28 | 2026-10-14 |
| Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST Imatinib Mesylate, Local resection - Gastrointestinal Stromal Tumor of Rectum | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 23 | 2023-10-01 | 2023-08-01 |
| Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma Dienogest 2 MG, N-acetyl cysteine - Uterine Leiomyoma | Phase 2 / Phase 3 | Completed | Ain Shams University | 40 | 2023-09-01 | 2024-12-16 |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis Relugolix Combination Tablet - Uterine Fibroids, Endometriosis | Phase 3 | Recruiting | Sumitomo Pharma Switzerland GmbH | 1000 | 2023-08-14 | 2025-08-06 |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) Pimicotinib(ABSK021), Placebo - Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis | Phase 3 | Active not recruiting | Abbisko Therapeutics Co, Ltd | 94 | 2023-04-27 | 2026-05-04 |
| A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Narlumosbart, Denosumab - Giant Cell Tumor of Bone | Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 146 | 2023-04-01 | 2023-04-19 |
Showing 20 of 158. Sign in to see all of them.
Gastrointestinal Stromal Tumors (38) · Sarcoma (26) · Myofibroma (19) · Osteosarcoma (19) · Liposarcoma (16) · Sarcoma, Synovial (15) · Fibrosarcoma (14) · Brenner Tumor (13) · Dupuytren Contracture (13) · Histiocytoma, Malignant Fibrous (13) · Leiomyosarcoma (13) · Ovarian Neoplasms (13) · Hemangiosarcoma (12) · Neurofibrosarcoma (11) · Leiomyoma (9)
Neoplasms by Histologic Type (156) · Neoplasms, Connective and Soft Tissue (155) · Neoplasms (149) · Neoplasms, Fibrous Tissue (54) · Skin and Connective Tissue Diseases (42) · Digestive System Diseases (40) · Digestive System Neoplasms (40) · Gastrointestinal Diseases (38) · Gastrointestinal Neoplasms (36) · Connective Tissue Diseases (35) · Neoplasms, Bone Tissue (30) · Neoplasms by Site (27) · Pathological Conditions, Signs and Symptoms (27) · Female Urogenital Diseases (26)
Imatinib Mesylate (21) · Doxorubicin (20) · Ifosfamide (15) · Paclitaxel (11) · Radiotherapy (10) · Sunitinib (9) · Carboplatin (8) · Cisplatin (8) · Etoposide (8) · Microbial Collagenase (7) · Bevacizumab (6) · Cyclophosphamide (6) · Methotrexate (6) · Disulfides (5) · Immunoglobulin G (5)
National Cancer Institute (NCI) (13) · European Organisation for Research and Treatment of Cancer - EORTC (9) · Gynecologic Oncology Group (7) · Children's Oncology Group (5) · Endo USA Inc., a Keenova Therapeutics Company (5) · Novartis Pharmaceuticals (5) · AB Science (4) · Deciphera Pharmaceuticals, LLC (4) · Assistance Publique - Hôpitaux de Paris (3) · InSightec (3) · Pfizer (3) · Philips Healthcare (3) · Asan Medical Center (2) · Blueprint Medicines Corporation (2) · Children's Cancer Hospital Egypt 57357 (2)
United States (75) · Canada (46) · France (38) · Germany (32) · United Kingdom (32) · Italy (31) · Netherlands (29) · Spain (29) · South Korea (26) · Australia (22) · Poland (22) · China (17) · Belgium (16) · Switzerland (16) · Sweden (15)
Robert Min, M.D. (3) · Anne Roberts, M.D. (2) · Elizabeth David, MD (2) · George Holland, M.D. (2) · Mark Shaman, M.D. (2) · Paolo G. Casali, MD (2) · Veronica Urdaneta, MD, MPPH (2) · Yoon-Koo Kang, MD, PhD (2) · A.N. Van Geel, MD (1) · Aaron R Weiss (1) · Abha Gupta, MD (1) · Achilleas Thoma, MD MSc FRCSC (1)
PMID 37185961, PMID 31401903, PMID 21941283, PMID 30633128, PMID 16110020, PMID 16110036, PMID 16368440, PMID 16394300, PMID 16515585, PMID 16624552, PMID 16876399, PMID 17046465, PMID 17264340, PMID 17267204, PMID 17336514, PMID 17634494, PMID 17906207, PMID 18286501, PMID 18430468, PMID 18640939, PMID 18653326, PMID 19303137, PMID 19596139, PMID 19620483, PMID 19726771, PMID 20434400, PMID 20489620, PMID 21050498, PMID 21140148, PMID 21529904, PMID 21967070, PMID 22119995, PMID 22204724, PMID 22204725, PMID 22421192, PMID 22453568, PMID 22480131, PMID 22665534, PMID 22954508, PMID 23177515, PMID 23190833, PMID 23219660, PMID 24140183, PMID 24470559, PMID 24618336, PMID 24638003, PMID 24747207, PMID 24942631, PMID 24957256, PMID 25421877
U10CA180886 (6), U10CA027469 (5), U10CA180868 (5), U10CA098543 (4), 2008 (3), 2015 (3), 2004 (2), 2009 (2), 2014 (2), 2016 (2), 2025 (2), U10CA032102 (2), U10CA101165 (2), U10CA180830 (2), U10CA180888 (2)